+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Companion Diagnostics Global Market Report 2024

  • PDF Icon

    Report

  • 200 Pages
  • December 2023
  • Region: Global
  • The Business Research Company
  • ID: 5751885
Companion diagnostics refer to in vitro diagnostic medical tests employed to assess the safety and effectiveness of a corresponding drug or biological product. These tests play a crucial role in helping healthcare professionals match patients with specific drugs or therapies.

The primary products and services in the companion diagnostics market include assays, kits, reagents, software, and related services. Assays, kits, and reagents find applications in various life science, environmental, and research laboratories. Assays are procedures used to examine substances for composition or quality, kits are collections of equipment and materials for specific purposes, and reagents are chemicals used in laboratory testing. Technologies such as polymerase chain reaction, next-generation sequencing, in situ hybridization, and immunohistochemistry are employed in companion diagnostics. These diagnostic tools are instrumental in identifying various cancer diseases like lung, breast, colorectal, leukemia, and melanoma. The primary users of companion diagnostics include pharmaceutical and biopharmaceutical companies, reference laboratories, and contract research organizations.

The companion diagnostics market research report is one of a series of new reports that provides companion diagnostics market statistics, including companion diagnostics industry global market size, regional shares, competitors with a companion diagnostics market share, detailed companion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the companion diagnostics industry. This companion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The companion diagnostics market size has grown exponentially in recent years. It will grow from $6.26 billion in 2023 to $7.52 billion in 2024 at a compound annual growth rate (CAGR) of 20.1%. The growth in the historical period can be attributed to the increased adoption of personalized medicine, the expansion of oncology and cancer therapies, heightened collaboration in pharmaceutical research and development, the implementation of precision medicine initiatives, and advancements in biomarker discovery.

The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $15.8 billion in 2028 at a compound annual growth rate (CAGR) of 20.4%. The growth in the forecast period can be attributed to the development of targeted therapies, advancements in infectious disease diagnostics, an increase in rare disease diagnostics, rising trends in biomarker-based drug development, the expansion of point-of-care testing, and the application of liquid biopsy. Major trends in the forecast period include advances in immunotherapy and immunology, the integration of AI and machine learning in diagnostics, product innovations, the adoption of Industry 4.0, and strategic collaborations.

The companion diagnostics market is anticipated to experience growth due to the increasing number of targeted therapies. Targeted therapy, which focuses on specific characteristics of cancer cells to hinder their growth and spread, is gaining prominence in cancer treatment. Companion diagnostics, through biological marker-based testing, play a crucial role in personalized cancer care by identifying eligibility for genome-targeted therapy. As per the European Society for Medical Oncology's April 2021 article, the estimated eligibility for genome-targeted therapy increased from 8.82% in previous years to 13.60% in 2020, reflecting the growing adoption of targeted therapies and driving the companion diagnostics market.

The growth of the companion diagnostics market is further propelled by the rising prevalence of chronic diseases. Companion diagnostics are increasingly used in chronic diseases or non-communicable diseases (NCDs) to tailor treatment plans, monitor disease progression, and predict drug resistance. The World Health Organization reported that 74% of global deaths, equivalent to 41 million, are caused by NCDs annually. Notably, diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes contribute significantly to this burden. The rising incidence of chronic diseases underscores the essential role of companion diagnostics in enhancing patient outcomes and contributing to the overall growth of the market.

A key trend in the companion diagnostics market is technological advancement, particularly the integration of artificial intelligence (AI). AI is being leveraged to develop more efficient drugs and advance companion diagnostics. The extensive genetic profiling data sets, continuously generated, enable the application of AI to identify insights into disease causes. For example, Toronto-based start-up Deep Genomics is utilizing AI to expedite the discovery of better medications for genetic illnesses. Through deep learning, scientists can explore the human genome, analyze billions of chemical compounds, and identify promising formulations for clinical trials. This application of AI in companion diagnostics aligns with the broader trend of technological innovation, driving advancements in the field.

Prominent companies in the companion diagnostics market are pioneering innovative treatment solutions, exemplified by products like therascreen KRAS PCR Mutation Analysis. This diagnostic test is designed for identifying non-small cell lung cancer (NSCLC) patients and is specifically tailored for Amgen's lung cancer therapy, LUMAKRAS (sotorasib). The test, performed on tumor tissue samples, delivers results promptly, typically within a few days. Laboratory Corporation of America Holdings, a leading US-based healthcare company, launched this companion diagnostic in July 2021. It plays a crucial role in identifying patients with NSCLC whose tumors harbor the specific genetic mutation KRAS G12C. Beyond facilitating targeted therapies, the test prevents patients from undergoing ineffective treatments with potential serious side effects.

In a strategic move, Agilent Technologies Inc., a major player in analytical laboratory solutions, acquired Resolution Bioscience for $695 million in April 2021. This acquisition fortified Agilent's position in next-generation sequencing (NGS)-based cancer diagnostics. Resolution Bioscience, a US-based healthcare research company, specializes in NGS technology, molecular biology, and cancer diagnostics. The acquisition empowered Agilent to meet the escalating demands of the precision medicine sector, reflecting the industry's commitment to advancing technologies and expanding capabilities in the companion diagnostics market.

Major companies operating in the companion diagnostics market include F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Abnova Corp., Amoy Diagnostics Co. Ltd., ARUP Laboratories, Bayer AG, Biomerieux SA, Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Biogenex Laboratories Inc., Caris Life Sciences, Cepheid Inc., Diaceutics PLC, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sividon Diagnostics GmbH, Sysmex Corporation, Ventana Medical Systems, Vermillion Inc.

North America was the largest region in the companion diagnostics market in 2023. The regions covered in the companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the companion diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The companion diagnostics market includes revenues earned by theranostics and monitoring tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Companion Diagnostics Market Characteristics3. Companion Diagnostics Market Trends And Strategies
4. Companion Diagnostics Market - Macro Economic Scenario
4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market
5. Global Companion Diagnostics Market Size and Growth
5.1. Global Companion Diagnostics Market Drivers and Restraints
5.1.1. Drivers Of The Market
5.1.2. Restraints Of The Market
5.2. Global Companion Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Companion Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Companion Diagnostics Market Segmentation
6.1. Global Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Assays, Kits And Reagents
Software And Services
6.2. Global Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Polymerase Chain Reaction
Next-Generation Sequencing
In Situ Hybridization
Immunohistochemistry
6.3. Global Companion Diagnostics Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
6.4. Global Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Pharmaceutical And Biopharmaceutical Companies
Reference Laboratories
Contract Research Organizations
7. Companion Diagnostics Market Regional And Country Analysis
7.1. Global Companion Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Companion Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Companion Diagnostics Market
8.1. Asia-Pacific Companion Diagnostics Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Companion Diagnostics Market
9.1. China Companion Diagnostics Market Overview
9.2. China Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Companion Diagnostics Market
10.1. India Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Companion Diagnostics Market
11.1. Japan Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.2. Japan Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Companion Diagnostics Market
12.1. Australia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Companion Diagnostics Market
13.1. Indonesia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Companion Diagnostics Market
14.1. South Korea Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.2. South Korea Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Companion Diagnostics Market
15.1. Western Europe Companion Diagnostics Market Overview
15.2. Western Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Companion Diagnostics Market
16.1. UK Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Companion Diagnostics Market
17.1. Germany Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Companion Diagnostics Market
18.5. France Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Companion Diagnostics Market
19.9. Italy Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Companion Diagnostics Market
20.13. Spain Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Companion Diagnostics Market
21.1. Eastern Europe Companion Diagnostics Market Overview
21.2. Eastern Europe Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Companion Diagnostics Market
22.1. Russia Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Companion Diagnostics Market
23.1. North America Companion Diagnostics Market Overview
23.2. North America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Companion Diagnostics Market
24.1. USA Companion Diagnostics Market Overview
24.2. USA Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Companion Diagnostics Market
25.1. Canada Companion Diagnostics Market Overview
25.2. Canada Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Companion Diagnostics Market
26.1. South America Companion Diagnostics Market Overview
26.2. South America Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Companion Diagnostics Market
27.1. Brazil Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Companion Diagnostics Market
28.1. Middle East Companion Diagnostics Market Overview
28.2. Middle East Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Companion Diagnostics Market
29.1. Africa Companion Diagnostics Market Overview
29.2. Africa Companion Diagnostics Market, Segmentation By Product And Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Companion Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Companion Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Companion Diagnostics Market Competitive Landscape And Company Profiles
30.1. Companion Diagnostics Market Competitive Landscape
30.2. Companion Diagnostics Market Company Profiles
30.2.1. F Hoffmann-La Roche Ltd.
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Agilent Technologies Inc.
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Qiagen NV
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Thermo Fisher Scientific Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Abbott Laboratories Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Global Companion Diagnostics Market Competitive Benchmarking32. Global Companion Diagnostics Market Competitive Dashboard33. Key Mergers And Acquisitions In The Companion Diagnostics Market
34. Companion Diagnostics Market Future Outlook and Potential Analysis
34.1 Companion Diagnostics Market In 2028 - Countries Offering Most New Opportunities
34.2 Companion Diagnostics Market In 2028 - Segments Offering Most New Opportunities
34.3 Companion Diagnostics Market In 2028 - Growth Strategies
34.3.1 Market Trend Based Strategies
34.3.2 Competitor Strategies
35. Appendix
35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer

Executive Summary

Companion Diagnostics Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on companion diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • All data from the report will also be delivered in an excel dashboard format.

Description:

Where is the largest and fastest growing market for companion diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

  • Markets Covered: 1) By Product And Service: Assays, Kits And Reagents; Software And Services 2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; In Situ Hybridization; Immunohistochemistry 3) By Indication: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Melanoma 4) By End-User: Pharmaceutical And Biopharmaceutical Companies; Reference Laboratories; Contract Research Organizations
  • Companies Mentioned: F Hoffmann-La Roche Ltd.; Agilent Technologies Inc.; Qiagen NV; Thermo Fisher Scientific Inc.; Abbott Laboratories Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F Hoffmann-La Roche Ltd.
  • Agilent Technologies Inc.
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories Inc.
  • Abnova Corp.
  • Amoy Diagnostics Co. Ltd.
  • ARUP Laboratories
  • Bayer AG
  • Biomerieux SA
  • Danaher Corporation
  • Guardant Health Inc.
  • Illumina Inc.
  • Myriad Genetics Inc.
  • Siemens Healthcare GmbH
  • Almac Group
  • Biogenex Laboratories Inc.
  • Caris Life Sciences
  • Cepheid Inc.
  • Diaceutics plc
  • Epic Sciences Inc.
  • Foundation Medicine Inc.
  • Genomic Health Inc.
  • Grail Inc.
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • Inivata Ltd.
  • Invivoscribe Inc.
  • MolecularMD Corporation
  • Natera Inc.
  • NeoGenomics Laboratories Inc.
  • Personal Genome Diagnostics Inc.
  • Precision Therapeutics Inc.
  • Prometheus Laboratories Inc.
  • Sividon Diagnostics GmbH
  • Sysmex Corporation
  • Ventana Medical Systems
  • Vermillion Inc.

Methodology

Loading
LOADING...